cc-97540
Cell therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04231747)
Timeline
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07015983 | Phase 2 | Jul 14, 2025 | Bristol-Myers Squibb |
| NCT06220201 | Phase 1 | Mar 28, 2024 | Bristol-Myers Squibb, Celgene |
| NCT05869955 | Phase 1 | Sep 13, 2023 | Bristol-Myers Squibb |
| NCT04231747 | Phase 1 | Jan 31, 2020 | Juno Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 3 | 2 | 2023 |
| Celgene | For profit | 1 | 0 | 1 | 2024 |
| Juno Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1